• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma.直接作用抗病毒药物可使慢性丙型肝炎感染和肝细胞癌患者产生良好的、持续的病毒学应答。
Korean J Intern Med. 2021 Mar;36(2):286-287. doi: 10.3904/kjim.2021.078. Epub 2021 Feb 25.
2
Cost-effectiveness of HCC surveillance among HCV patients after sustained virological response with direct-acting antivirals.
Liver Int. 2021 Dec;41(12):3036-3037. doi: 10.1111/liv.15072. Epub 2021 Oct 5.
3
The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?接受新型直接抗病毒药物治疗的患者实现持续病毒学应答后发生肝细胞癌的风险：我们应该为此担忧吗？
Expert Rev Anti Infect Ther. 2016 Nov;14(11):993-996. doi: 10.1080/14787210.2016.1243466.
4
Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.直接作用抗病毒药物治疗实现病毒学应答后丙型肝炎 3 期纤维化患者的肝细胞癌风险。
Liver Int. 2021 Dec;41(12):2885-2891. doi: 10.1111/liv.15032. Epub 2021 Aug 24.
5
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.AGA 临床实践更新：口服直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的相互作用：专家综述。
Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
6
Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.专业观点：直接作用抗病毒药物与肝细胞癌的发生和复发有关。
Liver Transpl. 2017 Dec;23(12):1593-1595. doi: 10.1002/lt.24960.
7
Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.全口服直接抗病毒方案对丙型肝炎病毒基因1型相关慢性肝病患者肝细胞癌发生率的影响
Oncology. 2017;93(2):92-98. doi: 10.1159/000470910. Epub 2017 Apr 28.
8
Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?对直接作用抗病毒药物的持续病毒学应答是否是丙型肝炎临床结局的有效替代终点？
Clin Infect Dis. 2021 Mar 1;72(5):787-788. doi: 10.1093/cid/ciaa147.
9
Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.慢性丙型肝炎病毒感染患者持续病毒学应答后肝癌发生的分子机制。
Viruses. 2018 Sep 28;10(10):531. doi: 10.3390/v10100531.
10
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.

本文引用的文献

1
EASL recommendations on treatment of hepatitis C: Final update of the series.EASL 丙型肝炎治疗建议：系列的最终更新。
J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15.
2
Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma.直接作用抗病毒治疗联合或不联合丙型肝炎相关肝细胞癌的疗效和安全性比较。
Korean J Intern Med. 2021 Mar;36(2):292-304. doi: 10.3904/kjim.2019.297. Epub 2020 Apr 3.
3
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新：美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
4
Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.系统评价与荟萃分析：直接作用抗病毒治疗对合并肝细胞癌的丙型肝炎患者的疗效。
Aliment Pharmacol Ther. 2020 Jan;51(1):34-52. doi: 10.1111/apt.15598. Epub 2019 Dec 6.
5
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.直接作用抗病毒治疗慢性丙型肝炎和肝细胞癌患者的持续病毒学应答：系统评价和荟萃分析。
J Hepatol. 2019 Sep;71(3):473-485. doi: 10.1016/j.jhep.2019.04.017. Epub 2019 May 13.
6
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?我们是否应该在治疗肝癌的同时治愈丙型肝炎病毒？
Liver Int. 2018 Dec;38(12):2108-2116. doi: 10.1111/liv.13918. Epub 2018 Jul 21.
7
Hepatitis C virus infection.丙型肝炎病毒感染。
Nat Rev Dis Primers. 2017 Mar 2;3:17006. doi: 10.1038/nrdp.2017.6.

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma.

作者信息

Sohn Won

机构信息

Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Korean J Intern Med. 2021 Mar;36(2):286-287. doi: 10.3904/kjim.2021.078. Epub 2021 Feb 25.

DOI:10.3904/kjim.2021.078
PMID:33725434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7969074/
Abstract
摘要